From: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
Additional tests** versus Aptima, n = | Additional costs versus Aptima, € | |
---|---|---|
Lower values for costs* (− 25%) and prevalence (10.5%) | ||
Hybrid Capture® 2 | 265,652 | 283,277,525.29 € |
Cobas® 4800 | 276,698 | 2,294,970.33 € |
Higher values for costs* (+ 25%) and lower value for prevalence (10.5%) | ||
Hybrid Capture® 2 | 265,652 | 442,621,133.27 € |
Cobas® 4800 | 276,698 | 3,585,891.13 € |
Lower values for costs* (− 25%) and higher value for prevalence (25.4%) | ||
Hybrid Capture® 2 | 243,924 | 432,074,832.70 € |
Cobas® 4800 | 230,360 | 1,910,159.13 € |
Higher values for costs* (+ 25%) and prevalence (25.4%) | ||
Hybrid Capture® 2 | 243,924 | 675,116,926.10 € |
Cobas® 4800 | 230,360 | 2,984,623.65 € |